Literature DB >> 22588794

Fasciocutaneous free flaps are more reliable than muscle free flaps in lower limb trauma reconstruction: experience in a single trauma center.

Foti Sofiadellis1, David S Liu, Angela Webb, Kirsty Macgill, Warren Matthew Rozen, Mark W Ashton.   

Abstract

BACKGROUND: Muscle (M) and fasciocutaneous (FC) free flaps are frequently used options in the reconstruction of traumatic lower limb injuries. The use of one flap over another has remained the topic of controversy in the literature. With a large experience, we sought to evaluate key outcomes of M versus FC free flap reconstructions in lower limb trauma in a single trauma center.
METHODS: A consecutive 7- year review of all free flap reconstructions for lower limb trauma performed at the Royal Melbourne Hospital was conducted. Patient data were prospectively entered into a unit database and retrospectively reviewed.
RESULTS: One hundred three patients underwent 105 free flap reconstructions (M = 48 and FC = 57) in lower limb trauma. We experienced a rate of 2.9% total flap failures and 11.4% partial flap losses. Total flap failures represented 6.3% M and 0% FC flaps. The partial flap failures included 15.8% of M and 5.3% of FC flaps. Latissimus dorsi (40% of M group) and radial forearm free flaps (67% of FC group) were most commonly used in each group. There was a statistically significant difference between groups in rates of reoperation (M = 44% versus FC = 16%), postoperative infection (M = 38% versus FC = 12%), fracture nonunion (M = 40% versus FC = 21%), and donor site morbidity (M = 25% versus FC = 4%). Nonstatistically significant differences were encountered with higher rates of osteomyelitis (M = 14.6% versus FC = 10.5%), unplanned bone graft (M = 14.6 versus FC = 10.5%), and inability to bear full weight at 1 year (M = 30.2% versus FC = 17.0%) found in the M group. In our cohort, M flaps used for metal coverage resulted in higher rates of reoperation, postoperative infections, and flap loss than FC flaps (M = 61% versus FC = 25%, p < 0.05).
CONCLUSION: Statistically higher complication rates in key reliability markers were found in the M free flap group. This study found FC free flaps to be more reliable for reconstruction of lower limb injuries in a major trauma center. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2012        PMID: 22588794     DOI: 10.1055/s-0032-1313764

Source DB:  PubMed          Journal:  J Reconstr Microsurg        ISSN: 0743-684X            Impact factor:   2.873


  6 in total

1.  [Free fasciocutaneous parascapular flap. Coverage of extensive skin and soft tissue defects].

Authors:  C Sachs; M Lehnhardt; A Daigeler; O Goertz
Journal:  Unfallchirurg       Date:  2015-10       Impact factor: 1.000

2.  Factors affecting the outcome of lower extremity osteomyelitis treated with microvascular free flaps: an analysis of 65 patients.

Authors:  Duy Quang Thai; Yeon Kyo Jung; Hyung Min Hahn; Il Jae Lee
Journal:  J Orthop Surg Res       Date:  2021-08-27       Impact factor: 2.359

3.  Reconstruction of the lower extremity using free flaps.

Authors:  Min Jo Kang; Chul Hoon Chung; Yong Joon Chang; Kyul Hee Kim
Journal:  Arch Plast Surg       Date:  2013-09-13

4.  Stromal Cell-Derived Factor-1α Alleviates Calcium-Sensing Receptor Activation-Mediated Ischemia/Reperfusion Injury by Inhibiting Caspase-3/Caspase-9-Induced Cell Apoptosis in Rat Free Flaps.

Authors:  Li Song; Li-Na Gao; Jun Wang; Swosti Thapa; Yong Li; Xiao-Bo Zhong; Hong-Wei Zhao; Xue-Rong Xiang; Fu-Gui Zhang; Ping Ji
Journal:  Biomed Res Int       Date:  2018-01-11       Impact factor: 3.411

Review 5.  Contemporary approach to soft-tissue reconstruction of the lower extremity after trauma.

Authors:  Matthew R Zeiderman; Lee L Q Pu
Journal:  Burns Trauma       Date:  2021-07-30

6.  Muscle vs. Fasciocutaneous Microvascular Free Flaps for Lower Limb Reconstruction: A Meta-Analysis of Comparative Studies.

Authors:  Vladimir Mégevand; Domizio Suva; Morad Mohamad; Didier Hannouche; Daniel F Kalbermatten; Carlo M Oranges
Journal:  J Clin Med       Date:  2022-03-11       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.